Participated · Equity · Mar 2026

Verily builds an AI-native precision health platform that transforms multimodal health data into insights, models, and actions intended to make healthcare more personalized, predictive, and precise. The company plans to accelerate that platform strategy following a $300 million investment and a legal restructure from an LLC to Verily Health Inc. Verily has been expanding commercial relationships—announcing collaborations with Samsung’s Galaxy Watch, Salesforce, UCHealth, the University of Colorado Anschutz, and RefinedScience—for biomarker development, clinical research acceleration, and enterprise precision health solutions. Alphabet remains an investor and, after the round, holds a significant minority position rather than a controlling stake. The company positions itself at the intersection of technology, data science, and healthcare to drive AI-enabled research and care transformation.

Participated · Equity · Apr 2025

hellocare.ai offers a unified, enterprise-ready virtual care platform that combines hardware, software, AI, and an EHR integration engine to deliver AI-Assisted Virtual Nursing, Virtual Sitting, Virtual Consultation, Ambient Documentation, digital whiteboards, patient engagement, Hospital-at-Home, RPM, and Digital Clinic. The company says its end-to-end, in-house technology stack enables rapid customization and integration for health systems. hellocare.ai is already deployed across 70+ health systems and is being rolled out enterprise-wide at AdventHealth across more than 50 hospitals and over 13,000 patient rooms. Bon Secours Mercy Health and UCHealth both participate as investors and customers, illustrating alignment between product roadmap and provider needs. The company plans to use new funding to scale rapidly, deepen its AI capabilities, and expand deployments with leading health systems. Headquartered in Clearwater, Florida, hellocare.ai positions itself as a replacement for fragmented point solutions by delivering measurable ROI and operational impact.

Participated · Equity · Apr 2022

Eon offers a cloud-based patient management platform that captures and longitudinally tracks patients at risk for future catastrophic diagnoses across multiple disease states. The platform leverages computational linguistics and data science models to identify incidental findings in radiology reports and provides care navigators with intuitive workflows for patient outreach and follow-up adherence. Eon is used by over 45 health systems and 400 hospital facilities across the U.S., with notable partners including LifePoint Health, HCA Healthcare, Ascension, Cleveland Clinic, and SCL Health. Led by CEOs Christine Spraker and Dr. Aki Al-Zubaidi, the company intends to use new funding to accelerate growth in key business areas. As part of the investment, UCHealth will begin a phased implementation of Eon across its hospitals and imaging centers.

Participated · Series B · Jul 2021

BioIntelliSense, led by CEO James Mault, MD, offers continuous health monitoring and clinical intelligence for Remote Patient Monitoring through medical-grade wearable devices and an advanced Data-as-a-Service (DaaS) platform. The platform captures multi-parameter vital signs, physiological biometrics, and symptomatic events to deliver high-resolution patient trending and reporting. Its FDA-cleared BioSticker™ and medical-grade BioButton® enable simple remote monitoring and early detection. Advanced analytics on the platform give clinicians access to actionable, medical-grade data to enable care at home. The company says it will use new funds to support continued growth and global expansion of its wearable devices and data services for scalable remote care. The business is based in Denver, Colorado.

Participated · Equity · Mar 2021

Riva Health builds a mobile cardiology application that measures and manages hypertension by capturing a high-resolution blood-pulse waveform (BPW) via fingertip photoplethysmography (PPG) using a phone camera. The company couples this novel measurement technology with interventions delivered by its licensed healthcare providers to enable higher-fidelity remote patient management and broader access to premium heart care. Led by CEO Dag Kittlaus and co-founder Tuhin Sinha, PhD, Riva is completing comprehensive validation of its measurement technology with world experts and is working with the FDA for marketing clearance. The company plans to launch the beta of its flagship app in summer 2021 and is hiring for its engineering team. Riva intends to use recently raised funds to expand operations.